Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease

Abstract

Objectives: Visfatin and lipocalin-2 are novel adipokines associated with insulin resistance (IR) and obesity-related metabolic disorders. We compared lipocalin-2 and visfatin concentrations between patients with coronary heart disease (CHD) and control subjects and evaluated their association with cardiovascular risk factors. Methods: We examined serum visfatin, lipocalin-2 levels, and cardiovascular risk factors in 91 subjects (49 patients with angiographically confirmed CHD versus 42 age-and gender-matched control participants). Results: Circulating lipocalin-2 levels were significantly higher in patients with CHD compared with the control subjects (82.6G38.7 ng/ml versus 43.8G27.8 ng/ml; P!0.001). However, visfatin levels were not significantly different between patients with CHD and control subjects. Serum lipocalin-2 levels were positively associated with weight (rZ0.26; PZ0.036), fasting insulin (rZ0.36; PZ0.003), and IR (rZ0.33; PZ0.007), whereas these levels showed a negative correlation with high-density lipoprotein (HDL) cholesterol (rZK0.30; PZ0.016) after adjustment for gender and body mass index. However, visfatin levels were not associated with any variables of the metabolic syndrome. The multiple regression analysis showed that lipocalin-2 levels were independently associated with HDL cholesterol and IR (R 2 Z0.199). Furthermore, the multiple logistic regression analysis showed that systolic blood pressure, IR, and lipocalin-2 levels were independently associated with CHD. Conclusions: Serum lipocalin-2 levels were significantly elevated in patients with CHD and were independently associated with CHD. The present findings suggest that the measurement of serum lipocalin-2 levels may be useful for assessing CHD risk.

Serum Visfatin Levels and Coronary Artery Disease

“…The results of our study are suggestive of increased serum visfatin levels as an indicator of coronary artery disease (3,7,8,(13)(14)(15)(16)20,24,26,30,32,33,36) . The association has been first identified in patients with carotid artery disease (2,14) and results of different studies including visfatin and coronary artery disease have been published in recent years (7,15,26,27) .…”

“…The findings of our study population when compared with the controls supported a prominent endothelial dysfunction in the study group. However, in a study by Choi et al (24) , circulating visfatin levels were not found to be significantly related with cardiovascular risk factors such as obesity, hypertension, lipid profile, and insülin resistance. Additionally, the auhors findings were not significantly different between patients with heart disease and control subjects (24) .…”

“…It has been shown a positive correlation between the visceral adipose tissue visfatin gene expression and BMI and a negative correlation between BMI and subcutaneous fat visfatin (34) . Plazma visfatin levels are associated with age, weight, BMI, and waist-to-hip ratio (24,35,36) . However, in the present study we failed to find a correlation between serum visfatin levels and BMI.…”

Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification

“…Previous studies on diabetes (Kang et al, 2010) and CHD (Choi et al, 2008) have reported a positive correlation between the serum visfatin levels and insulin resistance; moreover, Chang et al (2010) discovered a positive correlation between the visfatin mRNA expression in visceral adipose tissues and insulin resistance. The results of our study are in accordance with these results; that is, the IRI was positively correlated with the serum visfatin levels in patients with CAC, indicating the important role played by visfatin in the insulin-resistance mechanism.…”

Diagnostic and Prognostic Significance of Neutrophil Gelatinase- Associated Lipocalin and Pentraxin-3 in Acute Coronary Syndrome

“…In the study by Choi et al (37), serum NGAL levels were determined to be significantly higher in patients with CAD than in the healthy population. Similarly in another study, serum NGAL levels showed an increasing tendency in CAD and AMI, although this was not significant.…”